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Background: Although major depressive disorder is usually treated with
antidepressants, only 50–70% of the patients respond to this treatment. This study
applied Jacobson and Truax’s (1991) methodology (reliable change index, RCI) to a
sample of depressive patients being treated with one of two antidepressants to evaluate
their functioning and the effect of certain variables such as severity and age.
Method: Seventy-three depressive patients medicated with Escitalopram (n = 37) or
Duloxetine (n = 36) were assessed using the Hamilton depression rating scale over a
24-week period.
Results: They indicate that the RCI stabilizes in an absolute way starting in week 16, and
it is not until week 24 that all of the patients become part of the functional population. We
found limited statistical significance with respect to the RCI and the external variables.
Conclusion: Our study suggests the need to accompany the traditional statistical
methodology with some other clinical estimation systems capable of going beyond
a simple subtraction between pre and posttreatment values. Hence, it is concluded
that RCI estimations could be stronger and more stable than the classical statistical
techniques.
Keywords: reliable change index, depression, remission, longitudinal, clinical significant change
INTRODUCTION
Major depressive disorder (MDD), which is a highly prevalent and disabling disorder that is
associated with major personal and societal costs, is the second cause of disability worldwide.
This worldwide prevalence and disability justifies the importance of investigating the treatments
available (Driessen et al., 2015). While depression is more prevalent in women, single individuals,
and those of low socioeconomic status (Schulz and Arora, 2015), MDD frequently co-occurs with
other psychiatric disorders (Holma et al., 2014).
While there are several effective treatments for depression, antidepressant drugs are the most
common. However, up to 60% of the patients with MDD do not respond satisfactorily to an
initial antidepressant trial (Kasper and Montgomery, 2013), leaving them half symptomatic and
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functionally impaired. Unfortunately, the choice of
antidepressant for a patient is a matter of trial and error, as
there is little empirical evidence for choosing one treatment over
another (Bruder et al., 2014).
The patients must remain on their antidepressant for up
to 8 weeks before knowing whether they will respond to
that particular drug. This risk may prolong distress, increase
morbidity and mortality, and increase the burden on health
professionals (Kemp et al., 2008). For this reason, several
researchers have tried to find variables that could predict
antidepressant responses and grouped them into subject, severity,
and clinical variables (Gudayol-Ferré et al., 2010).
Regarding the subject variables, we examine the relationships
between variables such as age, years of formal education,
premorbid intelligence, and genetics and MDD-related cognitive
impairment. For the effects of age on remission, Reynolds
et al. (1998) examined treatment outcome differences when
considering age at the onset of the first lifetime episode of
recurrent major depression in elderly patients. They found that
early-onset patients required 5–6 weeks more than late-onset
patients before achieving remission, and they also exhibited a
higher proportion of suicide attempts.
Furthermore, high levels of education correlate with low
levels of depression. It has also been found that lower IQ
scores are associated with increased risks of schizophrenia, severe
depression, and other non-affective psychoses (Zammit et al.,
2004).
Three types of genetic variables are usually analyzed in relation
to MDD, the first being genetic polymorphism. There exists a
functional polymorphism in the 5HTTLPR serotonin transporter
gene that is associated with the polymorphic region. This gene
produces two alleles, namely, a long (l) allele and a short (s) allele.
The short allele (s) is associated with a higher risk of psychotic
symptoms during a depressive episode (Stamm et al., 2013).
More recently, an A/G SNP (rs25531) was identified within the
insertion fragment of the 5HTTLPR region that defines a triallelic
system (La, Lg, and S), among which La is the highest expressing
allele. Some studies have shown that this allele presents a better
response to an SSRI (selective serotonin reuptake inhibitor) (Yu
et al., 2002). Finally, we find the COMT gene (the catechol-
O-methyltransferase), which has the functional Val108/158Met
polymorphism that produces two alleles, namely, the Val (allele
G) and the Met (allele A) variants. The Val gene has a small
indirect effect on the clinical response to citalopram. Moreover,
the Met/Met gene has a higher risk of non-remission in 6–8 weeks
(Arias et al., 2006). Regarding disease severity, there are several
factors, such as age at the first episode, number of past depression
episodes, and number of comorbid anxiety disorders, that can
influence the remission of depression.
As for the age at the first episode, Dew et al. (1997) reported
that elderly patients who were older when they experienced
their first depression episode exhibit a more rapid and sustained
response profile. The recurrence of depression episodes is another
important factor that may influence the remission of depression.
Many individuals with recurrent MDD fail to show complete
interepisodic recovery and, in fact, show more chronic episodes
(Wilson et al., 2014). Beyond the high rates of coexistence,
comorbid anxiety has often been cited as a clinically relevant
problem owing to its impact on acute treatment response in late-
life depression. Thus, several studies have found that a greater
severity of anxiety symptoms is associated with an increased risk
of withdrawal from treatment, a decreased response to acute
antidepressant treatment, and longer response and remission
times (Steffens and McQuoid, 2005).
Finally, with respect to the third group (clinical variables),
the psychopharmacological treatment being administered and
the speed of response exhibited by the subjects (fast, slow, or
non-responders) are considered. It has been determined that
escitalopram is better tolerated and superior to duloxetine in the
acute treatment of MDD (Wade et al., 2007). With regard to the
speed of response, there exist various patterns of recovery from
the illness with an important variability among patients regarding
both the speed of response and remission (Stassen et al., 2007).
Usually, the patients are classified as fast, oscillating, or slow
(Gudayol-Ferré et al., 2013).
To evaluate the efficacy of the treatments, statistical
comparisons between the mean changes resulting from
the treatments (Jacobson and Truax, 1991) are used. In
neuropsychological and clinical assessments, in many situations,
a person completes the same psychological measures on two
or more occasions. In such a situation, test score gains are
hypothesized to exist independent of actual changes in a person’s
ability on the construct being measured by the test (Calamia
et al., 2012; Marco et al., 2014; Wolpert et al., 2015; Egger et al.,
2016a,b; Müller et al., 2016)
Nonetheless, the reliable change index (RCI) approach is still
uncommon among clinical researchers not only in psychology,
but in most health fields. This approach exhibits two properties
that make it especially appealing. The first is the individualized
study of each patient’s clinical progression, which entails not
only the specific knowledge of their clinical condition but also
implies changing from a contrast with respect to the mean
(commonly criticized with no counterproposals) to a contrast
with respect to the patients themselves. Second is the possibility
to classify patients as functional or dysfunctional, which allows
us to conduct a rare second analysis. It does not suffice to know
whether the mean or median of a clinical indicator is significantly
or marginally improved when compared to their pretreatment
value. Rather, it must be known which variables intervene in the
non-change evidence and which variables influence change. Put
more succinctly, the RCI approach allows for the analysis of the
implications of the complementary variables when identifying
those patients who have improved and those who have not. It is
not reasonable to think that the application of one treatment is
the only source of variation, especially in applied clinical research
where primary and secondary controls are limited.
Despite the current precedents in applying the RCI (Moleiro
and Beutler, 2009; Lilja et al., 2016; Beiwinkel et al., 2017; Brooks
et al., 2017; Foki et al., 2018), it has not been used extensively.
That is, it has not been used to generate a secondary analysis to
search for variables that may become improvement catalysts or
hindering variables beyond the effect of the treatment.
The purpose of the current study is to identify which factors
are related to remission in subjects diagnosed with MDD and
Frontiers in Psychology | www.frontiersin.org 2 August 2018 | Volume 9 | Article 1406
fpsyg-09-01406 August 2, 2018 Time: 19:18 # 3
Cañete-Massé et al. Clinical Significant Change in Depression
undergoing psychopharmacological treatment, i.e., duloxetine or
escitalopram. The level of remission is defined as the estimation
of clinically significant change by Jacobson and Truax (1991), and
hence, we identify the following specific objectives:
- To study the level of remission based on clinically
significant changes in a 24-week follow-up.
- To analyze the effects of applying three cut-off points used
in the estimations of the clinically significant change to
determine which subjects become part of the functional
population after the treatment and to identify the temporal
moment in which this change occurs.
- To study the effects of age, the recurrence of the depression
episodes, the level of education, the premorbid intellectual
coefficient, the comorbid anxiety disorders, the genetic
polymorphism, the age at the first episode and the response
pattern of the drugs in the clinically significant change.
- To study whether the two types of drugs, i.e., duloxetine




The sample was comprised of 73 depressive patients who
were recruited for the study. The treatments were assigned
pseudorandomly, such that the first subject recruited in a
subgroup was administered one treatment, while the second
subject received the other treatment. One group received 60 mg
per day of duloxetine (n = 37), and the other group received
10 mg per day of escitalopram (n = 36). Consequently, the final
design was an experimental factorial mixed design with matched
groups, one receiving the duloxetine treatment and the other
receiving the escitalopram treatment.
Participants
The present study is a 24-week follow-up of subjects who
participated in a clinical trial designed to assess the possible
effects of treatments using SSRIs and SNRIs (selective
noradrenaline reuptake inhibitors) on cognitive functions
in antidepressant drug-naïve patients with MDD (Herrera-
Guzmán et al., 2009). The 101 patients were included in
the study if they met the DSM-IV criteria for MDD. The
inclusion criteria were as follows: (i) a diagnostic confirmation
based on the mini-international neuropsychiatric interview
(MINI) (Sheehan et al., 1998); (ii) a score of 18 points or
higher on the Hamilton depression rating scale (HAM-D-17)
(Hamilton, 1967); (iii) an age between 20 and 50 years; and (iv)
a finding of being antidepressant-drug naïve and free of other
psychopharmacological compounds. Patients were excluded if
they failed to meet the DSM-IV criteria or had a past history
of any of the following disorders: posttraumatic, obsessive-
compulsive, schizophrenia, psychotic, delusional, bipolar, or
substance abuse. Similarly, subjects with any present or past
disease involving the central nervous system were also excluded.
Additional exclusion criteria included diabetes; hypertension;
cardiac, hepatic, pulmonary, and renal disease; and systemic
infectious diseases. Women entering the trial could not be
pregnant, and they had to be free of any oral contraceptives.
Patients were also excluded if they showed an inefficient response
to the pharmacological treatment after 4 weeks, i.e., the response
to treatment on the treated (TOT) was defined as a 50% or greater
reduction on the HAMD-17 in week four compared to the HAM-
D-17 baseline score. Of the 101 recruited patients, 73 completed
the study, while 28 abandoned or withdrew from the study
for various reasons. Consequently, the escitalopram group was
comprised of 37 patients, and the duloxetine group included 36
patients. All participants completed the registration forms during
the follow-up weeks. The sample’s demographic information is
presented in Table 1. The homoscedastic condition is met in all
cases, and no differences between the variables are apparent. The
protocol was approved by the ethics committee of the Michoacán
Mental Health Center (Centro Michoacano de Salud Mental, in
Spanish).
Instruments
All sampled participants were assessed by means of several
psychological tests that assessed specific psychometric
characteristics. These included the following
• Depression severity: Hamilton Reduced Depression Scale
(HAM-D-17) (Bagby et al., 2004).
• Premorbid intellectual verbal functioning: WAIS III
vocabulary subtest (Wechsler, 1997).
• Demographic and clinical questionnaire: a questionnaire
generated ad hoc for this procedure.
• Genotyping: Genomic DNA was extracted from
venous blood samples using a standard protocol. The
Val108/158Met (rs4680) COMT polymorphism was
genotyped by 5′-exonucleaseassay using TaqMan SNP
genotyping assay-on-demand. A 5HTTLPR triallelic
system was also performed.
Procedure
Once the recruited patients were assessed, the administration
of the assessments occurred throughout the 24-week period to
patients in the two groups, i.e., the 60 mg/day of duloxetine
group (36 patients) and the 10 mg/day of escitalopram group (37
patients). All patients were clinically assessed by the psychiatrist
in weeks 4, 8, 12, 16, 20, and 24 to control the clinical efficacy and
safety of the treatment. At the end of the trial, all subjects were
assessed again using the HAM-D-17 scale to evaluate the effects
of SSRIs and SNRIs. The analysis of the clinical data was blind to
the subjects’ genotype, and the genotype analysis was blind to the
subjects’ clinical data.
In all cases, regular clinical supervision and reliability
estimates were conducted between investigators of the
administration and correction processes of the scales. In all
cases, the reliability values exceeded.92.
Statistical Analysis
Traditional methods used to evaluate treatment efficacy have
been deemed problematic since the 1980s (Ronk et al., 2016).
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TABLE 1 | T-Test comparison between treatment groups of descriptive and clinical variables.
Variable Escitalopram mean (SD) n = 37 Duloxetine mean (SD) n = 36 t-Test df p
Age 32.91 (8.73) 33.21 (8.61) 0.299 71 0.881
Years of formal education 11.63 (3.71) 11.40 (3.93) 0.260 71 0.795
WAIS III vocabulary score 33.86 (7.61) 33.24 (6.71) 0.368 71 0.714
HAM-D-17 baseline score 25.30 (4.04) 25.1 (5.28) 0.130 71 0.897
HAM-D-17 after treatment score 0.58 (0.87) 0.78 (1.52) 0.685 71 0.493
Age at first depressive episodes 21.72 (8.65) 19.21 (8.84) 1.223 71 0.225
Number of past depressive episodes 3.81 (4.76) 3.59 (3.47) 0.217 71 0.820
Number of comorbid anxiety disorders 1.11 (0.85) 0.86 (0.88) 1.207 71 0.231
df, degrees of freedom; p, significance (p two tailed).




where X2 is the posttest score for each patient, X1 is the pretest
score for the same patient, and Sdiff describes the spread of the
distribution of change scores that would be expected if no actual
change occurred. An RCI over 1.96 would be unlikely to occur
(p < 0.05) without actual change.
They proposed a methodology to classify the subjects into
functional or dysfunctional populations according to three cut-
off points following the empirical criteria presented in the next
section. To analyze the effect of the complementary variables (age,
premorbid intelligence, genotyping, type of remission, drug, age
at first episode, number of past episodes, comorbid disorders,
and years of formal education) on the observed distribution
of the RCI, we used nonparametric (Mann-Whitney’s U or
Kruskal-Wallis’ H) and parametric (Student’s t, Snedecor’s F,
ANOVA, or Pearson’s rxy) estimates and contrasts, depending on
the conditions of the application and the characteristics of the
observed distributions.
RESULTS
To estimate the RCI we used Jacobson and Truax’s (1991)
methods. However, being only interested in one tail of the normal
distribution, we used the reference value to measure the clinically
significant change of 1.64 as a unilateral contrast result. The
following values were used: Sdiff = 1.737, rxx = 0.81, and SE = 1.228
i S1 = 2.818. Table 2 presents the descriptive values of the
estimations of the RCI for every week.
Table 2 presents a clinically significant change in weeks 24, 20,
16, and 10. In the other weeks there is no evidence of such change
for any of the participants. It is further noted that in week 12, one
subject dropped with respect to week 10 and then improved in
week 14. This improvement can be explained by the loss in week
10 (n = 14).
The mean and the standard deviation of the control
population were estimated as a mean of the observed means
reported in the different papers. This estimation was obtained
from Herrera-Guzmán et al. (2010a,b) (n = 37), who obtained a
mean of 3.2 and a standard deviation of 1.91; Gilley et al. (1995)
(n = 54), who obtained a mean of 6.4 and a standard
deviation of 6.7; and Reynolds and Kobak (1995) (n = 118),
who obtained a mean of 3.67 and a standard deviation
of 3.11.
The mean of our sample’s dysfunctional population is 21.51,
and its standard deviation is 2.818. To calculate the Hamilton
scale cut-off point for the distribution of the dysfunctional
population, we used the distribution from the sample studied.
Thus, the following values were obtained according to the
previously discussed three criteria.
A
(















Table 3 displays the frequency and percentage of switching to
the functional population following the indications of the three
cut-off points. Considering the type of disease being treated,
the most proper cut-off point would be c because, with respect
to this disorder, both populations overlap. As presented in
Table 3, in week 24, all subjects were within the functional
population.
The bivariate analysis was based on the RCI calculated above
and the variables that could have modulated this remission,
specifically, subject, severity, and clinical variables. However,
we are only interested in the weeks with unremitting subjects,
including week 12.
Table 4 presents the bivariate analysis of the quantitative
subject variables. In all cases, a Pearson correlation
was conducted. As evidenced by the table, none of the
analyses are statistically significant. Therefore, we can
assume that none of these external variables affect the RCI
estimation.
Table 5 displays the bivariate analysis of the RCI
in different weeks and the genetic polymorphism.
Table 6 presents the bivariate analysis of the RCI in
the different weeks and the Rs25531. Table 7 presents
the analysis of the RCI with the COMT gene. As noted
from the p-values, there is no significant relation in any
week.
Table 8 presents the bivariate analysis between the age
at first episode, the number of past episodes, the number
of comorbid anxiety disorders, and the RCI in weeks 12,
10, 8, 6, 4, and 2. We also see a statistically significant
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TABLE 2 | Descriptive statistics of the reliable clinical index for every week of treatment.
n Minimum Maximum x̄ SD
RCIH2 68 −13.82 0.00 −5.14 2.61
RCIH4 63 −12.09 −1.15 −6.95 2.50
RCIH6 60 −13.24 0.00 −7.71 2.85
RCIH8 59 −14.39 −1.73 −8.70 2.67
RCIH10 14 −9.21 −2.30 −6.37 1.94
RCIH12 58 −13.82 −0.58 −9.30 2.80
RCIH16 51 −14.39 −3.45 −9.99 2.41
RCIH20 46 −15.54 −4.03 −10.69 2.43
RCIH24 44 −16.12 −5.76 −11.29 2.15
x̄, mean; SD, standard deviation; RCI, reliable change index.
TABLE 3 | Frequency and percentage of switch to the functional population following the cut-off points A, B, and C.
Cut-off point A frequency (%) Cut-off point B frequency (%) Cut-off point C frequency (%)
H2 Switch functional 50 (70.4) 17 (23.9) 28 (39.4)
Non-functional 18 (25.4) 51 (71.8) 40 (56.3)
Missing 3 (4.2) 3 (4.2) 3 (4.2)
H4 Switch functional 58 (81.7) 33 (46.5) 44 (62.0)
Non-functional 5 (7.0) 30 (42.3) 19 (26.8)
Missing 8 (11.3) 8 (11.3) 8 (11.3)
H6 Switch functional 55 (77.5) 41 (57.7) 50 (70.4)
Non-functional 5 (7.0) 19 (26.8) 10 (14.1)
Missing 11 (15.5) 11 (15.5) 11 (15.5)
H8 Switch functional 55 (77.5) 51 (71.8) 54 (76.1)
Non-functional 4 (5.6) 8 (11.3) 5 (7.0)
Missing 12 (16.9) 12 (16.9) 12 (16.9)
H10 Switch functional 11 (15.5) 5 (7.0) 8 (11.3)
Non-functional 3 (4.2) 9 (12.7) 6 (8.5)
Missing 57 (80.3) 57 (80.3) 57 (80.3)
H12 Switch functional 55 (77.5) 51 (71.8) 53 (74.6)
Non-functional 3 (4.2) 7 (9.9) 5 (7.0)
Missing 13 (18.3) 13 (18.3) 13 (18.3)
H16 Switch functional 51 (71.8) 47 (66.2) 50 (70.4)
Non-functional 4 (5.6) 1 (1.4)
Missing 20 (28.2) 20 (28.2) 20 (28.2)
H20 Switch functional 46 (64.8) 44 (62.0) 45 (63.4)
Non-functional 2 (2.8) 1 (1.4)
Missing 25 (35.2) 25 (35.2) 25 (35.2)
H24 Switch functional 44 (62.0) 44 (62.0) 44 (62.0)
Missing 27 (38.0) 27 (38.0) 27 (38.0)
Switch functional: patients who, according to the cut-off points, switched to the functional population. Non-functional: patients who, according to the cut-off points,
remained in the dysfunctional population. Missing: patients who were lost at a specific week.
relationship (p = 0.049) in Table 8 between the variable age
at first episode and the RCI in week two. Accordingly, in
week two, the age at first episode influenced the remission
of depression. As evidenced in the correlation, there exists a
positive relation between these two variables, such that the
younger someone is when they suffer their first episode, the
better the prognosis, i.e., the higher the RCI. With respect
to the number of past depressive disorders and the number
of comorbid anxiety disorders, there is no statistical relation
between these variables and the RCI in any week. Therefore,
we conclude that neither of these variables influenced the
remission of depression in this sample when calculated using
the RCI).
Finally, with respect to the clinical variables, Table 9 presents
the bivariate analysis between the types of pharmacological
treatment administered and the RCI in the different weeks.
As evidenced by the table, there is a statistically significant
relation between the type of treatment and the RCI in
week two (p = 0.001). The table indicates that the patients
undergoing the escitalopram treatment have lower RCI absolute
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TABLE 4 | Pearson correlation, degrees of freedom, p-value and effect size of the bivariate analysis between the RCI in weeks 12, 10, 8, 4, and 2 and the quantitative
variables of the subject.
RCI Age Years of formal education Premorbid intelligence
rxy df p rxy df p rxy df p
Week 12 −0.007 69 0.961 0.017 69 0.898 −0.004 69 0.975
Week 10 Insufficient sample size (n = 14)
Week 8 0.054 69 0.687 −0.140 69 0.291 −0.120 69 0.365
Week 6 0.000 69 0.997 −0.056 69 0.673 −0.120 69 0.362
Week 4 0.088 69 0.492 −0.052 69 0.688 −0.116 69 0.367
Week 2 −0.105 69 0.395 0.023 69 0.852 −0.198 69 0.105
RCI, reliable change index; rxy, Pearson’s correlation; df, degrees of freedom; p, significance (p two tailed).
TABLE 5 | Mean, SD, bivariate analysis (ANOVA/Kruskall Wallis test), and homogeneity test of the RCI in all the weeks and the variable genetic polymorphism.
RCI Poly. x̄ (SD) Contrast df p
Week 12 (F = 3.830, p < 0.05)∗ ss −9.11 (3.69) H = 0.340 2 0.843
sl −9.60 (1.82)
LL −8.95 (2.49)
Week 10 Insufficient sample size (n = 14)
Week 8 (F = 3.536, p < 0.05)∗ ss −8.66 (3.41) H = 0.274 2 0.872
sl −8.91 (2.17)
LL −8.25 (1.49)
Week 6 (F = 1.869, p = 0.164)∗ ss −7.76 (3.43) F = 0.601 2/56 0.552
sl −7.99 (2.42)
LL −6.78 (2.32)
Week 4 (F = 0.058, p = 0.943)∗ ss −7.67 (2.46) F = 1.788 2/60 0.176
sl −6.39 (2.40)
LL −6.70 (2.68)
Week 2 (F = 1.046, p = 0.357)∗ ss −5.75 (2.75) F = 1.189 2/60 0.311
sl −4.75 (2.70)
LL −4.76 (1.76)
x̄, mean; SD, standard deviation; RCI, reliable change index; ()∗, homoscedasticity analysis; F, statistical value of F of Snedecor; H, Kruskal-Wallis test; df, degrees of
freedom; p, significance (p two tailed), ss, sl, and LL, different genotypes of the genetic polymorphism.
TABLE 6 | Mean, SD, bivariate analysis (t-test/U de Mann Whitney test), and homogeneity test of the RCI in all the weeks and the variable Rs 25531.
RCI Rs 25531 x̄ (SD) Contrast df p
Week 12 (F = 6.657, p = 0.013)∗ LA −9.25 (1.94) U = 370.500 1 0.435
No LA −9.35 (3.50)
Week 10 Insufficient sample size (n = 14)
Week 8 (F = 5.44, p = 0.023)∗ LA −8.67 (1.93) U = 416.500 1 0.778
No LA −8.73 (3.27)
Week 6 (F = 1.228, p = 0.261)∗ LA −7.40 (2.47) t = 0.831 58 0.409
No LA −8.02 (3.20)
Week 4 (F = 1.392, p = 0.243)∗ LA −6.49 (2.65) t = 1.495 61 0.140
No LA −7.43 (2.28)
Week 2 (F = 0.102, p = 0.751)∗ LA −4.67 (2.46) t = 1.592 66 0.116
No LA −5.67 (2.70)
x̄x, mean; SD, standard deviation; RCI, reliable change index; ()∗, homoscedasticity analysis; U, statistical value of U de Mann Whitney; t, T-Test; df, degrees of freedom;
p, significance (p two tailed); LA and no LA, different genotypes of the Rs 25531.
values and, therefore, a worse prognosis in week two. This
suggests that the patients treated with duloxetine experienced
a quicker clinically significant change than those treated
with escitalopram, whereas in week four, both antidepressants
were equally effective in producing a clinically significant
change.
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TABLE 7 | Mean, SD, bivariate analysis (ANOVA/Kruskall Wallis test), and homogeneity test of the RCI in all the weeks and the variable COMT.
RCI COMT. x̄ (SD) Contrast df p
Week 12 (F = 0.737, p = 0.484)∗ AG −9.14 (2.86) F = 0.403 2/52 0.670
GG −9.74 (2.85)
AA −8.88 (1.62)
Week 10 Insufficient sample size (n = 14)
Week 8 (F = 1.189, p = 0.313)∗ AG −8.94 (2.64) F = 0.840 2/53 0.438
GG −8.81 (3.00)
AA −7.49 (1.41)
Week 6 (F = 0.793, p = 0.458)∗ AG −7.80 (3.10) F = 0.410 2/54 0.666
GG −8.03 (2.84)
AA −6.91 (1.88)
Week 4 (F = 0.588, p = 0.559)∗ AG −7.10 (2.24) F = 1.704 2/57 0.191
GG −7.26 (2.61)
AA −5.34 (2.99)
Week 2 (F = 3.473, p = 0.037)∗ AG −5.11 (2.60) H = 0.994 2 0.608
GG −5.50 (3.04)
AA −4.28 (0.732)
x̄, mean; SD, standard deviation; RCI, reliable change index; ()∗, homoscedasticity analysis; F, statistical value of F of Snedecor; H, Kruskal-Wallis test; df, degrees of
freedom; p, significance (p two tailed); AG, GG, and AA, different values of the genotype of COMT.
TABLE 8 | Pearson’s correlation, degrees of freedom, p-value, and effect size of the different quantitative variables of severity.
RCI Age at the first episode Number of past depressive episodes Number of comorbid anxiety disorders
Correlation rxy df p R2 rxy df p rxy df p
Week 12 0.024 69 0.861 − −0.137 69 0.303 −0.024 69 0.855
Week 10 Insufficient sample size (n = 14)
Week 8 0.064 69 0.632 − −0.062 69 0.640 0.048 69 0.716
Week 6 0.020 69 0.881 − −0.052 69 0.691 −0.013 69 0.992
Week 4 0.091 69 0.479 − 0.135 69 0.291 0.016 69 0.899
Week 2 0.239 69 0.049 0.057 0.066 69 0.590 −0.215 69 0.078
x̄, mean; SD, standard deviation; RCI, reliable change index; rxy, Pearson’s; df, degrees of freedom; p, significance (p two tailed).
TABLE 9 | Mean, bivariate analysis, and homogeneity test between the variables type of treatment and RCI in all the weeks of treatment.
RCI Drug x̄ (SD) Contrast df p r
Week 12 (F = 1.121, p = 0.294)∗ Duloxetine −9.18 (3.29) t = 0.281 55 0.780 −
Escitalopram −9.40 (2.56)
Week 10 Insufficient sample size (n = 14)
Week 8 (F = 0.497, p = 0.484)∗ Duloxetine −9.29 (2.85) t = 1.278 56 0.207 −
Escitalopram −9.36 (2.56)
Week 6 (F = 0.266, p = 0.608)∗ Duloxetine −7.61 (2.90) t = 0.251 57 0.803 −
Escitalopram −7.81 (2.89)
Week 4 (F = 1.392, p = 0.243)∗ Duloxetine −6.49 (2.65) t = 1.495 61 0.140 −
Escitalopram −7.43 (2.28)
Week 2 (F = 3.45, p = 0.068)∗ Duloxetine −6.62 (2.53) t = 3.45 60 0.001 0.165
Escitalopram −4.42 (2.24)
x̄, mean; SD, standard deviation; RCI, reliable change index; ()∗, homoscedasticity estimation; df, degrees of freedom; p, significance (p two tailed).
Table 10 presents the bivariate analysis of the RCI in
the different weeks and the type of remission and the speed
of remission. There is a statistically significant relation in
weeks eight (p = 0.021), six (p = 0.009), four (p < 0.001),
and two (p < 0.001). In week eight, it is evident that
the patients with a fast remission time experienced a more
clinically significant change (higher RCI) than did non-
responsive patients and patients with slower remission time.
Similarly, the same results are found in weeks six, four,
and two.
Frontiers in Psychology | www.frontiersin.org 7 August 2018 | Volume 9 | Article 1406
fpsyg-09-01406 August 2, 2018 Time: 19:18 # 8
Cañete-Massé et al. Clinical Significant Change in Depression
TABLE 10 | Mean, bivariate analysis (ANOVA), and homogeneity test of the variables RCI in the different weeks and the type of remission.
RCI Type of remission x̄ (SD) Contrast df p r
Week 12 (F = 1.407, p = 0.254)∗ Fast −10.00 (2.607) F = 2.125 2/52 0.130 −
Slow −9.65 (2.03)
Non-response −8.33 (2.91)
Week 10 Insufficient sample size (n = 14)
Week 8 (F = 0.683, p = 0.510)∗ Fast −9.92 (2.84) F = 4.185 2/53 0.021 0.136
Slow −8.74 (2.23)
Non-response −7.45 (2.43)
Week 6 (F = 0.58, p = 0.522)∗ Fast −8.87 (2.41) F = 5.153 2/54 0.009 0.160
Slow −8.31 (2.38)
Non-response −6.23 (2.88)
Week 4 (F = 0.340, p = 0.713)∗ Fast −8.63 (1.77) F = 43.372 2/57 <0.001 0.603
Slow −8.13 (1.55)
Non-response −4.18 (1.55)
Week 2 (F = 5.234, p = 0.008)∗ Fast −7.92 (2.26) H = 34,419 2 <0.001 0.763
Slow −4.27 (1.30)
Non-response −3.51 (1.20)
x̄, mean; SD, standard deviation; RCI, reliable change index; ()∗, homoscedasticity estimation; F, ANOVA test; H, Kruskal-Wallis test; df, degrees of freedom; p, significance
(p two tailed); r, effect size.
DISCUSSION
According with our results, it is important to emphasize that
the estimations clearly delineate the sustained remissions of
the patients treated with both drugs. Generally, applying the
different criteria demonstrates an equally high stability of this
result, meaning that, regardless of the criterion used, the
effect described herein remains unmodified. These results are
congruent with others (Jacobson and Truax, 1991) not only
in the field of MDD (Ozen et al., 2016) but in other fields
as well (Schütze et al., 2014; Montero et al., 2015; Ruiz-
Sancho et al., 2015; Skewes et al., 2015; de Oliveira et al.,
2017).
By studying the effect over the course of 24 weeks, we
obtained evidence that the RCI settled or stabilized in an
absolute way beginning in week 16 and the remission state
remained unmodified until the study’s end. The clinically
significant change occurred after week 16 of the antidepressant
treatment. Similarly, the results revealed slight differences
between the classification criteria, thus confirming Jacobson and
Truax’s (1991) proposal. Furthermore, as previously discussed,
only in week 24 can we assume that all patients are part
of the functional population. However, this consideration
is subject to considerable debate given the psychometric
criteria of the classification linked to the clinical diagnosis of
MDD.
Similarly, the statistical results regarding the behavior of
the RCI estimations are presented according to the different
external variables. In this case, the results revealed limited
statistical significance, which leads us to conclude that the levels
of remission estimated based on the RCI are not dependent
on external factors. Particularly, it is important to highlight the
lack of a relationship between the genetic markers analyzed and
the estimations of the RCI, a finding that is inconsistent with
the findings of other studies (Arias et al., 2006). Furthermore,
it is also important to emphasize that no link was found
between the number of comorbid anxiety disorders and the
estimations of RCI, another finding that is inconsistent with
those of previous research (Gudayol-Ferré et al., 2010). Despite
these inconsistencies, it is noted that, in week two, there is a
statistically significant effect between the estimations of the RCI
and the age at first episode. Specifically, the patients whose first
episode occurred at a younger age demonstrated a higher absolute
RCI value. According to the data obtained, our findings are not
consistent with the data presented by Reynolds et al. (1998)
because, in our sample, the younger patients presented better
prognoses. However, this disagreement should be interpreted
with caution given that the effect size is low (R2 = 0.057). This
effect swings from week four onward, where the values of the RCI
are equal for both age groups. Our results also differ from those of
Dew et al. (1997), perhaps due to the use of the RCI instead of the
traditional methods. A statistical effect was also found between
the RCI estimation and the speed of the response to the drugs in
weeks eight, six, four, and two.
In addition to the study of external variables, it would be
interesting to predict remission in patients treated with one
specific antidepressant. Using the RCI estimations, we can study
which external variables affect remission and individualize the
pharmacological treatment for every individual, thus reducing
the recurrence and the residual symptomatology of MDD.
Finally, as a brief summary, it is noted that the effects
due to the RCI are extremely fast. Hence, it is assumed that
these pharmacological treatments significantly reduce the MDD
symptomatology, and thus, both treatments appear to be highly
effective. In relation to the analysis of speed of response, our
findings suggest the need of reconsideration of the classification
criteria in order to establish more accurately the slow, fast, and
non-respondent patients.
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One last aspect to consider is the clinical impact this type
of analysis promotes in applied clinical research. In the most
basic research, its contribution is probably more limited since it
consists of highly controlled trials. However, in the case of applied
clinical research, the question is quite different. In fact, the group
analysis presents serious limitations in terms of prognosis and
evaluation of each patient and is usually conceptualized as a
comparison with the control group. Clinically, it is debatable
whether global comparisons respond to the characteristics of a
particular patient. In the formulated proposal, the control is the
patient himself and a theoretical distribution of functionality that
does not depend on any other data. In the clinical evaluation, the
subject is only checked against himself. It can be argued that our
data do not reveal relevant statistical significance with external
factors that may mediate or moderate the clinical effect. This is
true, in our case, but it only indicates the possibility of conducting
this type of contrasts and subsequent analyses, which, in applied
research, are usually only performed at the group level rather than
the level of the individual patient. The non-significance does not
imply that the technique has not the necessary flexibility to be
useful in applied clinical research.
With respect to limitations, while the simple sizes used are
obviously small, this is justified by the fact that this is an applied
investigation and it analyzes only the subjects who completed
the entire 24-week protocol for every drug. Conversely, as
the assignment of treatment to the patient was not strictly
randomized, it is a source of possible bias. Finally, the design
proposed may be much more interesting if at least one group
had been incorporated to assess the RCI derived from a dual
intervention, e.g., drug plus psychotherapy. To conclude, while
the presence of a control group may offer some data on natural
changes after 24 weeks, this project is not assessing the treatment’s
efficacy, and therefore, this is a minor issue.
The limitations notwithstanding, our study has certain
relevant properties. It is one of the earliest reports to assess a
new use of the RCI analysis and the interpretation of the data-
base. Specifically, this study applies Jacobson and Truax’s (1991).
clinically significant change and conducts individual analyses of
the variabilities that arise when examining the subjects’ responses
to the two pharmacological treatments. Similarly, a statistical
study was conducted on how other variables, such as age or
comorbid anxiety disorders, affect the RCI.
CONCLUSION
Based on the aforementioned RCI results, the following
conclusions are drawn:
• The clinical results of the two treatments are especially
good, and the RCI rapidly reflects the effects of the
treatment.
• It is possible to clarify those subjects who experienced a
clinically significant change and those subjects who did not.
• This effect was not sustained in all subjects because of the
variability over the different weeks.
• The potential benefits of exploring predictors for individual
antidepressants are considerable because patients can then
be matched to the medication to which they are most likely
to respond.
However, in our sample, this variability cannot be explained
by the effect of different measured external variables such as
age, premorbid intelligence, or genetic or clinical variables. That
notwithstanding, the use of the RCI has proven useful for
assessing the possible effects of those or other clinically relevant
variables.
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